Natural History of Hepatocellular Carcinoma and Current Treatment Options

Seminars in Nuclear Medicine

Volumn 38, Issue 2, 2008, Pages

  Raoul, Jean Luc ^a  

^a Centre Régional de Lutte Contre Le Cancer   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; ALCOHOL; DOXORUBICIN; IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL I 131; IODINE 131; MITOMYCIN; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; SORAFENIB; TAMOXIFEN; UNCLASSIFIED DRUG; YTTRIUM 90;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CHEMOEMBOLIZATION; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG DOSE COMPARISON; DYSPNEA; EUROPE; FEVER; GEOGRAPHY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IRON METABOLISM; JAPAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; OBESITY; OVERALL SURVIVAL; PROGNOSIS; RADIOFREQUENCY ABLATION; TOBACCO; UNITED STATES; VIRUS HEPATITIS;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COCARCINOGENESIS; HEPATITIS, VIRAL, HUMAN; IODINE RADIOISOTOPES; IODIZED OIL; LIVER NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 38549137014     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2007.10.004     Document Type: Article

References (29)

1. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
2. Bosch F.X., Ribes J., Diaz M., et al. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127 (2004) S27-S34
3. El-Serag H.B. Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology 127 (2004) S27-S34
4. Sangiovanni A., Del Ninno E., Fasani P., et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126 (2004) 1005-1014
5. Bréchot C. Pathogenesis of hepatitis B virus related hepatocellular carcinoma: Old and new paradigms. Gastroenterology 127 (2004) S56-S61
6. Lok A.S. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 127 (2004) S303-S309
7. Callee E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity and mortality from cancer in a prospective studied cohort of US adults. N Engl J Med 348 (2003) 1625-1638
8. Fattovich G., Stroffolini T., Zagni I., et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (2004) S35-S50
9. Llovet J.M., Bru C., and Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 19 (1999) 329-338
10. CLIP. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31 (2000) 840-845
11. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. J Hepatol 35 (2001) 421-430
12. Song T.J., Ip E.W.K., and Fong Y. Hepatocellular carcinoma: Current surgical management. Gastroenterology 127 (2004) S248-S260
13. Lau W.Y., Leung T.W., Ho S.K., et al. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial. Lancet 353 (1999) 797-801
14. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
15. Livraghi T., Giorgio A., Marin G., et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injections. Radiology 197 (1995) 101-108
16. Lencioni R., Allgaier H.P., Cioni D., et al. Small hepatocellular carcinoma in cirrhosis: Randomized controlled trial of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 228 (2003) 235-240
17. Lin S.M., Lin C.J., Lin C.C., et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 127 (2004) 1714-1723
18. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization: a multicenter randomized trial. Hepatology 35 (2002) 1164-1171
19. Llovet J.M., Real M.I., Montana X., et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma. Lancet 359 (2002) 1734-1739
20. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003) 429-442
21. 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26 (1997) 1156-1161
22. Raoul J.L., Guyader D., Bretagne J.F., et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial Iodine-131-iodized oil versus medical support. J Nucl Med 35 (1994) 1782-1787
23. 131I-lipiodol in treatment of hepatocellular carcinoma: Results of a phase II trial. Int J Radiat Oncol Biol Phys 64 (2006) 745-750
24. Sundram F.X., Jeong J.M., Zanzonico P., et al. Trans-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: An IAEA sponsored multi-centre phase I study. World J Nucl Med 1 (2002) 5-11
25. 188Re-HDD/Lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med 46 (2005) 60-66
26. Geschwind J.F.H., Salem R., Carr B.I., et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127 (2004) S194-S205
27. Ando E., Tanaka M., Yamashita F., et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95 (2002) 588-595
28. Bruix J., Sherman M., Llovet J.M., et al., EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35 (2001) 421-430
29. Thomas M.B., and Zhu A.X. Hepatocellular carcinoma: The need for progress. J Clin Oncol 23 (2005) 2892-2899